0N70 Stock Overview
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.80 |
| 52 Week High | €33.00 |
| 52 Week Low | €22.98 |
| Beta | 0.26 |
| 1 Month Change | -0.74% |
| 3 Month Change | -10.12% |
| 1 Year Change | -15.72% |
| 3 Year Change | -8.28% |
| 5 Year Change | 20.45% |
| Change since IPO | 129.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0N70 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | 2.2% |
| 1Y | -15.7% | -29.1% | 0.9% |
Return vs Industry: 0N70 exceeded the UK Biotechs industry which returned -29.5% over the past year.
Return vs Market: 0N70 underperformed the UK Market which returned 0.6% over the past year.
Price Volatility
| 0N70 volatility | |
|---|---|
| 0N70 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0N70 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0N70's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,426 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| 0N70 fundamental statistics | |
|---|---|
| Market cap | €1.39b |
| Earnings (TTM) | €127.00m |
| Revenue (TTM) | €684.60m |
9.0x
P/E Ratio1.7x
P/S RatioIs 0N70 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0N70 income statement (TTM) | |
|---|---|
| Revenue | €684.60m |
| Cost of Revenue | €404.30m |
| Gross Profit | €280.30m |
| Other Expenses | €153.30m |
| Earnings | €127.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 3.21 |
| Gross Margin | 40.94% |
| Net Profit Margin | 18.55% |
| Debt/Equity Ratio | 126.7% |
How did 0N70 perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield1%
Payout RatioDoes 0N70 pay a reliable dividends?
See 0N70 dividend history and benchmarks| Biotest dividend dates | |
|---|---|
| Ex Dividend Date | May 08 2024 |
| Dividend Pay Date | May 13 2024 |
| Days until Ex dividend | 11 days |
| Days until Dividend pay date | 16 days |
Does 0N70 pay a reliable dividends?
See 0N70 dividend history and benchmarks